ARCHIVES

Patent Policies Need Revision, Study of Hopkins, CellPro Dispute Concludes;

This article is from The Cancer Letter archive.

Vol. 29 No. 02 | January 10, 2003

Download PDF Visit The Full Archive

Related Articles

A Conversation with MSKCC’s José Baselga: We Need to Increase Our Reach

September 27, 2013

FDA Declares Taxol Orphan Drug For KS; Can IVAX Break Bristol’s Exclusivity?

August 15, 1997

Weak Structure, Deficiencies, Cited In Dana-Farber Reviews

November 3, 1995

FY’78 Construction Requests $44 Million, Budget At $12 Million

December 2, 1977

NCI-Approved Clinical Trials Listed For June 2001

July 27, 2001

In Brief: UC Irvine Wins Grant For Trial Of One-Visit Cervical Cancer Screening, Treatment

November 6, 1998